Abeta; Alzheimer’s disease; Amyloid-β; Automated histology quantification; Dementia with Lewy bodies; Mini Mental State Examination; Post-translational modifications; Vascular dementia; Amyloid beta-Peptides; Isoaspartic Acid; Humans; Male; Female; Aged; Aged, 80 and over; Middle Aged; Brain/pathology; Brain/metabolism; Isoaspartic Acid/metabolism; Protein Processing, Post-Translational; Alzheimer Disease/pathology; Alzheimer Disease/genetics; Alzheimer Disease/metabolism; Amyloid beta-Peptides/metabolism; Lewy Body Disease/pathology; Lewy Body Disease/metabolism; Lewy Body Disease/genetics; Dementia, Vascular/pathology; Dementia, Vascular/metabolism; Brain; Dementia, Vascular; Lewy Body Disease; Pathology and Forensic Medicine; Neurology (clinical); Cellular and Molecular Neuroscience; Amyloid-beta
Abstract :
[en] The formation of amyloid-β (Aβ) aggregates in brain is a neuropathological hallmark of Alzheimer's disease (AD). However, there is mounting evidence that Aβ also plays a pathogenic role in other types of dementia and that specific post-translational Aβ modifications contribute to its pathogenic profile. The objective of this study was to test the hypothesis that distinct types of dementia are characterized by specific patterns of post-translationally modified Aβ variants. We conducted a comparative analysis and quantified Aβ as well as Aβ with pyroglutamate (pGlu3-Aβ and pGlu11-Aβ), N-truncation (Aβ(4-X)), isoaspartate racemization (isoAsp7-Aβ and isoAsp27-Aβ), phosphorylation (pSer8-Aβ and pSer26-Aβ) or nitration (3NTyr10-Aβ) modification in post mortem human brain tissue from non-demented control subjects in comparison to tissue classified as pre-symptomatic AD (Pre-AD), AD, dementia with Lewy bodies and vascular dementia. Aβ modification-specific immunohistochemical labelings of brain sections from the posterior superior temporal gyrus were examined by machine learning-based segmentation protocols and immunoassay analyses in brain tissue after sequential Aβ extraction were carried out. Our findings revealed that AD cases displayed the highest concentrations of all Aβ variants followed by dementia with Lewy bodies, Pre-AD, vascular dementia and non-demented controls. With both analytical methods, we identified the isoAsp7-Aβ variant as a highly abundant Aβ form in all clinical conditions, followed by Aβ(4-X), pGlu3-Aβ, pGlu11-Aβ and pSer8-Aβ. These Aβ variants were detected in distinct plaque types of compact, coarse-grained, cored and diffuse morphologies and, with varying frequencies, in cerebral blood vessels. The 3NTyr10-Aβ, pSer26-Aβ and isoAsp27-Aβ variants were not found to be present in Aβ plaques but were detected intraneuronally. There was a strong positive correlation between isoAsp7-Aβ and Thal phase and a moderate negative correlation between isoAsp7-Aβ and performance on the Mini Mental State Examination. Furthermore, the abundance of all Aβ variants was highest in APOE 3/4 carriers. In aggregation assays, the isoAsp7-Aβ, pGlu3-Aβ and pGlu11-Aβ variants showed instant fibril formation without lag phase, whereas Aβ(4-X), pSer26-Aβ and isoAsp27-Aβ did not form fibrils. We conclude that targeting Aβ post-translational modifications, and in particular the highly abundant isoAsp7-Aβ variant, might be considered for diagnostic and therapeutic approaches in different types of dementia. Hence, our findings might have implications for current antibody-based therapies of AD.
Disciplines :
Neurology
Author, co-author :
Schrempel, Sarah ; Paul Flechsig Institute - Centre of Neuropathology and Brain Research, University of Leipzig, Liebigstraße 19, 04103, Leipzig, Germany
Kottwitz, Anna Katharina ; Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany ; Center for Natural Product-based Therapeutics, Anhalt University of Applied Sciences, 06366, Köthen, Germany
Piechotta, Anke; Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany
Gnoth, Kathrin; Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany ; Center for Natural Product-based Therapeutics, Anhalt University of Applied Sciences, 06366, Köthen, Germany
Büschgens, Luca; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Georg-August-University, 37075, Göttingen, Germany
Hartlage-Rübsamen, Maike; Paul Flechsig Institute - Centre of Neuropathology and Brain Research, University of Leipzig, Liebigstraße 19, 04103, Leipzig, Germany
Morawski, Markus; Paul Flechsig Institute - Centre of Neuropathology and Brain Research, University of Leipzig, Liebigstraße 19, 04103, Leipzig, Germany
Schenk, Mathias; Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany
Kleinschmidt, Martin; Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany
Serrano, Geidy E; Civin Laboratory for Neuropathology, Brain and Body Donation Program, Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ, 85351, USA
Beach, Thomas G; Civin Laboratory for Neuropathology, Brain and Body Donation Program, Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ, 85351, USA
Rostagno, Agueda; Department of Pathology, New York University School of Medicine, New York, NY, USA
Ghiso, Jorge; Department of Pathology, New York University School of Medicine, New York, NY, USA
HENEKA, Michael ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB)
Walter, Jochen; Center of Neurology, Molecular Cell Biology, University Hospital Bonn, 53127, Bonn, Germany
Wirths, Oliver; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Georg-August-University, 37075, Göttingen, Germany
Schilling, Stephan; Department of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, 06120, Halle (Saale), Germany ; Center for Natural Product-based Therapeutics, Anhalt University of Applied Sciences, 06366, Köthen, Germany
Roßner, Steffen; Paul Flechsig Institute - Centre of Neuropathology and Brain Research, University of Leipzig, Liebigstraße 19, 04103, Leipzig, Germany. steffen.rossner@medizin.uni-leipzig.de
Federal State of Saxony Federal State of Saxony-Anhalt National Institute of Neurological Disorders and Stroke National Institute on Aging Arizona Department of Health Services Arizona Biomedical Research Commission Michael J. Fox Foundation for Parkinson’s Research German Research Foundation Universität Leipzig
Funding text :
We are grateful to the Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program for the provision of human brain tissue. The Program has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026, National Brain and Tissue Resource for Parkinson\u2019s Disease and Related Disorders), the National Institute on Aging (P30AG019610 and P30AG072980, Arizona Alzheimer\u2019s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer\u2019s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson\u2019s Research. This work was also supported by the German Research Foundation (DFG grants RO 2226/17-1 to S.R.; WA1477/6-6 to J.W. and SCHI 1437/4-1 to St.S.; GRK2824 and WI 3472/11-1 to O.W.). Sa.S. received a PhD student fellowship awarded by the Federal State of Saxony. A.K.K. received a PhD student fellowship awarded by the Federal State of Saxony-Anhalt. We thank S. Theil for hybridoma cell culture and purification of antibodies (1E4E11 and 5H11C10).Open Access funding enabled and organized by Projekt DEAL. Federal State of Saxony, Fellowship Sarah Schrempel, Federal State of Saxony-Anhalt, Fellowship Anna Katharina Kottwitz, National Institute of Neurological Disorders and Stroke, U24 NS072026, National Institute on Aging, P30AG019610 and P30AG072980, Arizona Department of Health Services, contract 211002, Arizona Biomedical Research Commission, contracts 4001, 0011, 05-901 and 1001, Michael J. Fox Foundation for Parkinson\u2019s Research, German Research Foundation, WA 1477/6-6, GRK2824, WI 3472/11-1, SCHI 1437/4-1, RO 2226/17-1.
E. Abramov I. Dolev H. Fogel G.D. Ciccotosto E. Ruff I. Slutsky Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses Nat Neurosci 2009 12 1567 1576 1:CAS:528:DC%2BD1MXhsVGlur%2FP 10.1038/nn.2433 19935655
A. Alexandru W. Jagla S. Graubner A. Becker C. Bäuscher S. Kohlmann et al. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation J Neurosci 2011 31 12790 12801 1:CAS:528:DC%2BC3MXhtFOhtrzI 10.1523/JNEUROSCI.1794-11.2011 21900558 6623394
O.N. Antzutkin R.D. Leapman J.J. Balbach R. Tycko Supramolecular structural constraints on Alzheimer’s beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance Biochemistry 2002 41 15436 15450 1:CAS:528:DC%2BD38XptFChtrk%3D 10.1021/bi0204185 12484785
S. Arezoumandan K.A.Q. Cousins D.T. Ohm M. Lowe M. Chen J. Gee et al. Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer’s disease Ann Clin Transl Neurol 2024 11 673 685 10.1002/acn3.51988 38263854 10963284
K. Arima K. Uéda N. Sunohara K. Arakawa S. Hirai M. Nakamura et al. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy Acta Neuropathol 1998 96 439 444 1:CAS:528:DyaK1cXmtFegtLc%3D 10.1007/s004010050917 9829806
K. Arima S. Hirai N. Sunohara K. Aoto Y. Izumiyama K. Uéda et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson’s disease and in dementia with Lewy bodies Brain Res 1999 843 53 61 1:CAS:528:DyaK1MXmvVGqt78%3D 10.1016/S0006-8993(99)01848-X 10528110
E.L. Ashby J.S. Miners S. Kumar J. Walter S. Love P.G. Kehoe Investigation of A β phosphorylated at serine 8 (pAβ) in Alzheimer’s disease, dementia with Lewy bodies and vascular dementia Neuropathol Appl Neurobiol 2015 41 428 444 1:CAS:528:DC%2BC2MXotlCgsLs%3D 10.1111/nan.12212 25556395
J. Attems J.B. Toledo L. Walker E. Gelpi S. Gentleman G. Halliday et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study Acta Neuropathol 2021 141 159 172 1:CAS:528:DC%2BB3MXjvVKqu7k%3D 10.1007/s00401-020-02255-2 33399945 7847437
M. Baba S. Nakajo P.H. Tu T. Tomita K. Nakaya V.M. Lee et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies Am J Pathol 1998 152 879 884 1:CAS:528:DyaK1cXivVKgsbc%3D 9546347 1858234
A.S. Bader M.U. Gnädig M. Fricke L. Büschgens L.J. Berger H.W. Klafki et al. Brain region-specific differences in amyloid-β plaque composition in 5XFAD mice Life (Basel) 2023 13 1053 1:CAS:528:DC%2BB3sXpvVKntb8%3D 10.3390/life13041053 37109582
Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C et al (2022) Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis 9:211–220. https://doi.org/10.14283/jpad.2022.21
T.G. Beach C.H. Adler L. Lue L.I. Sue J. Bachalakuri J. Henry-Watson et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction Acta Neuropathol 2009 117 613 634 10.1007/s00401-009-0538-8 19399512 2757320
T.G. Beach C.H. Adler L.I. Sue G. Serrano H.A. Shill D.G. Walker et al. Arizona study of aging and neurodegenerative disorders and brain and body donation program Neuropathology 2015 35 354 389 10.1111/neup.12189 25619230 4593391
A. Bluhm S. Schrempel S. Schilling S. von Hörsten A. Schulze S. Roßner et al. Immunohistochemical demonstration of the pGlu79 α-synuclein fragment in Alzheimer’s disease and its Tg2576 mouse model Biomolecules 2022 12 1006 1:CAS:528:DC%2BB38XhvF2iu77L 10.3390/biom12071006 35883562 9312983
B.D.C. Boon M. Bulk A.J. Jonker T.H.J. Morrema E. van den Berg M. Popovic et al. The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer’s disease Acta Neuropathol 2020 140 811 830 1:CAS:528:DC%2BB3cXhvVCltLrM 10.1007/s00401-020-02198-8 32926214 7666300
D.R. Borchelt G. Thinakaran C.B. Eckman M.K. Lee F. Davenport T. Ratovitsky et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo Neuron 1996 17 1005 1013 1:CAS:528:DyaK28XnsVCrtL0%3D 10.1016/s0896-6273(00)80230-5 8938131
Y. Bouter K. Dietrich J.L. Wittnam N. Rezaei-Ghaleh T. Pillot S. Papot-Couturier et al. N-truncated amyloid β (Aβ) 4–42 forms stable aggregates and induces acute and long-lasting behavioral deficits Acta Neuropathol 2013 126 189 205 1:CAS:528:DC%2BC3sXht1eks73I 10.1007/s00401-013-1129-2 23685882 3722453
H. Braak E. Braak Neuropathological stageing of Alzheimer-related changes Acta Neuropathol 1991 82 239 259 1:STN:280:DyaK387gtFOiug%3D%3D 10.1007/BF00308809 1759558
H. Braak E. Braak J. Bohl Staging of Alzheimer-related cortical destruction Eur Neurol 1993 33 403 408 1:STN:280:DyaK2c7jvFOrsg%3D%3D 10.1159/000116984 8307060
D.L. Brody S. Magnoni K.E. Schwetye M.L. Spinner T.J. Esparza N. Stocchetti et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain Science 2008 321 1221 1224 1:CAS:528:DC%2BD1cXhtVGgt7zE 10.1126/science.1161591 18755980 2577829
D.B. Bylund T.S. Huang Decomposition of phosphoserine and phosphothreonine during acid hydrolysis Anal Biochem 1976 73 477 485 1:CAS:528:DyaE28XktlSgtr8%3D 10.1016/0003-2697(76)90197-4 962058
E. Cabrera P. Mathews E. Mezhericher T.G. Beach J. Deng T.A. Neubert et al. Aβ truncated species: implications for brain clearance mechanisms and amyloid plaque deposition Biochim Biophys Acta Mol Basis Dis 2018 1864 208 225 1:CAS:528:DC%2BC2sXhsleksrjJ 10.1016/j.bbadis.2017.07.005 28711595
T. Chatterjee G. Das B.K. Chatterjee S. Ghosh P. Chakrabarti The role of protein-L-isoaspartyl methyltransferase (PIMT) in the suppression of toxicity of the oligomeric form of Aβ42, in addition to the inhibition of its fibrillization ACS Chem Neurosci 2023 14 2888 2901 1:CAS:528:DC%2BB3sXhsF2ku7nE 10.1021/acschemneuro.3c00281 37535852
H. Crehan B. Liu M. Kleinschmidt J.-U. Rahfeld K.X. Le B.J. Caldarone et al. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice Alzheimers Res Ther 2020 12 12 1:CAS:528:DC%2BB3cXhsFKktrc%3D 10.1186/s13195-019-0579-8 31931873 6958628
O. Crescenzi S. Tomaselli R. Guerrini S. Salvadori A.M. D'Ursi P.A. Temussi et al. Solution structure of the Alzheimer amyloid beta-peptide (1–42) in an apolar microenvironment. Similarity with a virus fusion domain Eur J Biochem 2002 269 5642 5648 1:CAS:528:DC%2BD38XptVymtbs%3D 10.1046/j.1432-1033.2002.03271.x 12423364
H. Cynis J.L. Frost H. Crehan C.A. Lemere Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges Mol Neurodegener 2016 11 48 1:CAS:528:DC%2BC2sXhvFWltr3E 10.1186/s13024-016-0115-2 27363697 4929720
R.B. DeMattos J. Lu Y. Tang M.M. Racke C.A. DeLong J.A. Tzaferis et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice Neuron 2012 76 908 920 1:CAS:528:DC%2BC38Xhsl2isrvN 10.1016/j.neuron.2012.10.029 23217740
M.I. Fonseca E. Head P. Velazquez C.W. Cotman A.J. Tenner The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age Exp Neurol 1999 157 277 288 1:CAS:528:DyaK1MXjs1Gnt78%3D 10.1006/exnr.1999.7058 10364440
J.L. Frost B. Liu M. Kleinschmidt S. Schilling H.-U. Demuth C.A. Lemere Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study Neurodegener Dis 2012 10 265 270 1:CAS:528:DC%2BC38XlvVOls74%3D 10.1159/000335913 22343072 3702016
J.L. Frost K.X. Le H. Cynis E. Ekpo M. Kleinschmidt R.M. Palmour et al. Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models Am J Pathol 2013 183 369 381 1:CAS:528:DC%2BC3sXhtFynt73J 10.1016/j.ajpath.2013.05.005 23747948 3730768
J.L. Frost B. Liu J.-U. Rahfeld M. Kleinschmidt B. O'Nuallain K.X. Le et al. An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice Neurobiol Aging 2015 36 3187 3199 1:CAS:528:DC%2BC2MXhsV2nt7zE 10.1016/j.neurobiolaging.2015.08.021 26453001 4641825
J.P. Fuller J.B. Stavenhagen S. Christensen F. Kartberg M.J. Glennie J.L. Teeling Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies Acta Neuropathol 2015 130 699 711 1:CAS:528:DC%2BC2MXhs1Cns7jP 10.1007/s00401-015-1484-2 26433971 4612324
D. Galasko L. Chang R. Motter C.M. Clark J. Kaye D. Knopman et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype Arch Neurol 1998 55 937 945 1:STN:280:DyaK1czktFCmsw%3D%3D 10.1001/archneur.55.7.937 9678311
W.R. Galpern A.E. Lang Interface between tauopathies and synucleinopathies: a tale of two proteins Ann Neurol 2006 59 449 458 1:CAS:528:DC%2BD28XjtV2lsbk%3D 10.1002/ana.20819 16489609
T. Geiger S. Clarke Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation J Biol Chem 1987 262 785 794 1:CAS:528:DyaL2sXksFyitQ%3D%3D 10.1016/S0021-9258(19)75855-4 3805008
J. Gerth S. Kumar A. Rijal Upadhaya E. Ghebremedhin C.A.F. von Arnim D.R. Thal et al. Modified amyloid variants in pathological subgroups of β-amyloidosis Ann Clin Transl Neurol 2018 5 815 831 1:CAS:528:DC%2BC1cXhtlWru7fP 10.1002/acn3.577 30009199 6043770
G.G. Glenner C.W. Wong Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem Biophys Res Commun 1984 120 885 890 1:CAS:528:DyaL2cXitVOntLw%3D 10.1016/S0006-291X(84)80190-4 6375662
K. Gnoth A. Piechotta M. Kleinschmidt S. Konrath M. Schenk N. Taudte et al. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology Alzheimers Res Ther 2020 12 149 1:CAS:528:DC%2BB3cXitlKiur%2FJ 10.1186/s13195-020-00719-x 33189132 7666770
K. Gnoth S. Geissler J. Feldhaus N. Taudte V. Ilse S. Zürner et al. Evidence for enhanced efficacy of passive immunotherapy against beta-amyloid in CD33-negative 5xFAD mice Biomolecules 2022 12 399 1:CAS:528:DC%2BB38XoslKnt7Y%3D 10.3390/biom12030399 35327591 8945487
I. Gueorguieva B.A. Willis L. Chua K. Chow C.S. Ernest J. Wang et al. Donanemab exposure and efficacy relationship using modeling in Alzheimer’s disease Alzheimers Dement (N Y) 2023 9 10.1002/trc2.12404 37388759 e12404
B.H.-O. Güttler H. Cynis F. Seifert H.-H. Ludwig A. Porzel S. Schilling A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues Amino Acids 2013 44 1205 1214 1:CAS:528:DC%2BC3sXktVOhsLY%3D 10.1007/s00726-012-1454-0 23344882
R.L. Hamilton Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry Brain Pathol 2000 10 378 384 1:STN:280:DC%2BD3cvotFWktw%3D%3D 10.1111/j.1750-3639.2000.tb00269.x 10885656
J. Hardy J.M. Schott Identifying genetic risk for amyloid-related imaging abnormalities Neurology 2024 102 1:CAS:528:DC%2BB2cXit1aju77O 10.1212/WNL.0000000000208096 38165303 e208096
M. Hartlage-Rübsamen M. Morawski A. Waniek C. Jäger U. Zeitschel B. Koch et al. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms Acta Neuropathol 2011 121 705 719 1:CAS:528:DC%2BC3MXmsVWrtro%3D 10.1007/s00401-011-0806-2 21301857 3098988
M. Hartlage-Rübsamen A. Bluhm A. Piechotta M. Linnert J.-U. Rahfeld H.-U. Demuth et al. Immunohistochemical evidence from APP-transgenic mice for glutaminyl cyclase as drug target to diminish pE-Abeta formation Molecules 2018 23 924 1:CAS:528:DC%2BC1cXhslGmsLbL 10.3390/molecules23040924 29673150 6017857
T. Hoffmann A. Meyer U. Heiser S. Kurat L. Böhme M. Kleinschmidt et al. Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer’s disease-studies on relation to effective target occupancy J Pharmacol Exp Ther 2017 362 119 130 1:CAS:528:DC%2BC2sXhsFOqsb3J 10.1124/jpet.117.240614 28446518
K. Inoue D. Hosaka N. Mochizuki H. Akatsu K. Tsutsumiuchi Y. Hashizume et al. Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-β in Alzheimer’s brain tissues by covalent chiral derivatized ultraperformance liquid chromatography tandem mass spectrometry Anal Chem 2014 86 797 804 1:CAS:528:DC%2BC3sXhvVGkur7N 10.1021/ac403315h 24283798
A. Jan O. Gokce R. Luthi-Carter H.A. Lashuel The ratio of monomeric to aggregated forms of Aβ40 and Aβ42 is an important determinant of amyloid-β aggregation, fibrillogenesis, and toxicity J Biol Chem 2008 283 28176 28189 1:CAS:528:DC%2BD1cXht1ans7zP 10.1074/jbc.M803159200 18694930 2661389
J.T. Jarrett E.P. Berger P.T. Lansbury The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease Biochemistry 1993 32 4693 4697 1:CAS:528:DyaK3sXksVKktL0%3D 10.1021/bi00069a001 8490014
M. Jucker L.C. Walker Alzheimer’s disease: from immunotherapy to immunoprevention Cell 2023 186 4260 4270 1:CAS:528:DC%2BB3sXhvFCgt7nL 10.1016/j.cell.2023.08.021 37729908 10578497
C. Kang Donanemab: first approval Drugs 2024 10.1007/s40265-024-02087-4 39404937 11196366
Kleinschmidt M, Schilling S, Rahfeld J-U et al. (2012) Diagnostic Antibody Assay(WO/2012/123562). https://patents.google.com/patent/DK2686346T3/da?oq=DK2686346T3. Accessed 19 Jun 2024
J. Köppen A. Schulze L. Machner M. Wermann R. Eichentopf M. Guthardt et al. Amyloid-beta peptides trigger aggregation of alpha-synuclein in vitro Molecules 2020 25 580 1:CAS:528:DC%2BB3cXksVamu74%3D 10.3390/molecules25030580 32013170 7037551
S. Kumar N. Rezaei-Ghaleh D. Terwel D.R. Thal M. Richard M. Hoch et al. Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer’s disease EMBO J 2011 30 2255 2265 1:CAS:528:DC%2BC3MXlsVSjtr4%3D 10.1038/emboj.2011.138 21527912 3117653
S. Kumar O. Wirths S. Theil J. Gerth T.A. Bayer J. Walter Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer’s disease Acta Neuropathol 2013 125 699 709 1:CAS:528:DC%2BC3sXmsFeltb0%3D 10.1007/s00401-013-1107-8 23525537
S. Kumar O. Wirths K. Stüber P. Wunderlich P. Koch S. Theil et al. Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity Acta Neuropathol 2016 131 525 537 1:CAS:528:DC%2BC28XjtFChsr4%3D 10.1007/s00401-016-1546-0 26898910 4789232
S. Kumar J.L. Frost C.W. Cotman E. Head R. Palmour C.A. Lemere et al. Deposition of phosphorylated amyloid-β in brains of aged nonhuman primates and canines Brain Pathol 2018 28 427 430 10.1111/bpa.12573 29740941 8028592
S. Kumar A. Kapadia S. Theil P. Joshi F. Riffel M.T. Heneka et al. Novel phosphorylation-state specific antibodies reveal differential deposition of Ser26 phosphorylated Aβ species in a mouse model of Alzheimer’s disease Front Mol Neurosci 2020 13 1:CAS:528:DC%2BB3MXptVaqs7Y%3D 10.3389/fnmol.2020.619639 33519377 619639
S. Kumar C.A. Lemere J. Walter Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models Acta Neuropathol Commun 2020 8 118 1:CAS:528:DC%2BB3cXhsFShsrvJ 10.1186/s40478-020-00959-w 32727580 7388542
M.P. Kummer M. Hermes A. Delekarte T. Hammerschmidt S. Kumar D. Terwel et al. Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation Neuron 2011 71 833 844 1:CAS:528:DC%2BC3MXhtFKjtLvL 10.1016/j.neuron.2011.07.001 21903077
M.P. Kummer M.T. Heneka Truncated and modified amyloid-beta species Alzheimers Res Ther 2014 6 28 10.1186/alzrt258 25031638 4055046
Y.M. Kuo M.R. Emmerling A.S. Woods R.J. Cotter A.E. Roher Isolation, chemical characterization, and quantitation of Abeta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits Biochem Biophys Res Commun 1997 237 188 191 1:CAS:528:DyaK2sXlsVCru7g%3D 10.1006/bbrc.1997.7083 9266855
C. Landles K. Sathasivam A. Weiss B. Woodman H. Moffitt S. Finkbeiner et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease J Biol Chem 2010 285 8808 8823 1:CAS:528:DC%2BC3cXjtFShsLg%3D 10.1074/jbc.M109.075028 20086007 2838303
M. Mandler L. Walker R. Santic P. Hanson A.R. Upadhaya S.J. Colloby et al. Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer’s disease Acta Neuropathol 2014 128 67 79 1:CAS:528:DC%2BC2cXptVehtrg%3D 10.1007/s00401-014-1296-9 24861310
C.L. Masters G. Simms N.A. Weinman G. Multhaup B.L. McDonald K. Beyreuther Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc Natl Acad Sci U S A 1985 82 4245 4249 1:CAS:528:DyaL2MXktlGltr0%3D 10.1073/pnas.82.12.4245 3159021 397973
I.G. McKeith B.F. Boeve D.W. Dickson G. Halliday J.-P. Taylor D. Weintraub et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium Neurology 2017 89 88 100 10.1212/WNL.0000000000004058 28592453 5496518
D.L. Miller I.A. Papayannopoulos J. Styles S.A. Bobin Y.Y. Lin K. Biemann et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease Arch Biochem Biophys 1993 301 41 52 1:CAS:528:DyaK3sXhs1Klsro%3D 10.1006/abbi.1993.1112 8442665
V.A. Mitkevich I.Y. Petrushanko Y.E. Yegorov O.V. Simonenko K.S. Vishnyakova A.A. Kulikova et al. Isomerization of Asp7 leads to increased toxic effect of amyloid-β42 on human neuronal cells Cell Death Dis 2013 4 1:CAS:528:DC%2BC3sXhvVyktLjM 10.1038/cddis.2013.492 24287700 3847340 e939
M. Montalbano L. Majmundar U. Sengupta L. Fung R. Kayed Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer’s disease, progressive supranuclear palsy, and dementia with Lewy bodies Brain Pathol 2022 33 1:CAS:528:DC%2BB38XisVGrtrjE 10.1111/bpa.13112 36054524 9836371 e13112
M. Morawski M. Hartlage-Rübsamen C. Jäger A. Waniek S. Schilling C. Schwab et al. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer’s disease Acta Neuropathol 2010 120 195 207 1:CAS:528:DC%2BC3cXotVKnsb0%3D 10.1007/s00401-010-0685-y 20383514 2892616
M. Morawski S. Schilling M. Kreuzberger A. Waniek C. Jäger B. Koch et al. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer’s disease J Alzheimers Dis 2014 39 385 400 1:CAS:528:DC%2BC2cXhtFKls7k%3D 10.3233/JAD-131535 24164736
C. Mori E.T. Spooner K.E. Wisniewsk T.M. Wisniewski H. Yamaguch T.C. Saido et al. Intraneuronal Abeta42 accumulation in Down syndrome brain Amyloid 2002 9 88 102 1:CAS:528:DC%2BD38Xmt1Wlurs%3D 10.3109/13506120208995241 12440481
M.L. Moro M.J. Collins E. Cappellini Alzheimer’s disease and amyloid beta-peptide deposition in the brain: a matter of 'aging'? Biochem Soc Trans 2010 38 539 544 1:CAS:528:DC%2BC3cXjslams7k%3D 10.1042/BST0380539 20298218
M.L. Moro A.S. Phillips K. Gaimster C. Paul A. Mudher J.A.R. Nicoll et al. Pyroglutamate and isoaspartate modified amyloid-beta in ageing and Alzheimer’s disease Acta Neuropathol Commun 2018 6 3 1:CAS:528:DC%2BC1cXitFeqtLjF 10.1186/s40478-017-0505-x 29298722 5753481
S. Mukherjee K.A. Perez L.C. Lago S. Klatt C.A. McLean I.E. Birchall et al. Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer’s disease Brain Commun 2021 3 fcab028 1:CAS:528:DC%2BB3MXpvFOisbo%3D 10.1093/braincomms/fcab028 33928245 8062259
J.M. Nussbaum S. Schilling H. Cynis A. Silva E. Swanson T. Wangsanut et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β Nature 2012 485 651 655 1:CAS:528:DC%2BC38XnvVymsbc%3D 10.1038/nature11060 22660329 3367389
J. Orpiszewski N. Schormann B. Kluve-Beckerman J.J. Liepnieks M.D. Benson Protein aging hypothesis of Alzheimer disease FASEB J 2000 14 1255 1263 1:CAS:528:DC%2BD3cXjvFyjtL8%3D 10.1096/fasebj.14.9.1255 10834947
R. Perez-Garmendia G. Gevorkian Pyroglutamate-modified amyloid beta peptides: emerging targets for Alzheimer’s disease immunotherapy Curr Neuropharmacol 2013 11 491 498 1:CAS:528:DC%2BC3sXhsFOks7vK 10.2174/1570159X11311050004 24403873 3763757
A. Piechotta C. Parthier M. Kleinschmidt K. Gnoth T. Pillot I. Lues et al. Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy J Biol Chem 2017 292 12713 12724 1:CAS:528:DC%2BC2sXht1eqtLfF 10.1074/jbc.M117.777839 28623233 5535044
C.J. Pike D. Burdick A.J. Walencewicz C.G. Glabe C.W. Cotman Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state J Neurosci 1993 13 1676 1687 1:CAS:528:DyaK3sXks12murw%3D 10.1523/JNEUROSCI.13-04-01676.1993 8463843 6576726
L.D. Plant J.P. Boyle I.F. Smith C. Peers H.A. Pearson The production of amyloid beta peptide is a critical requirement for the viability of central neurons J Neurosci 2003 23 5531 5535 1:CAS:528:DC%2BD3sXltl2qs7Y%3D 10.1523/JNEUROSCI.23-13-05531.2003 12843253 6741264
E. Portelius N. Bogdanovic M.K. Gustavsson I. Volkmann G. Brinkmalm H. Zetterberg et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease Acta Neuropathol 2010 120 185 193 1:CAS:528:DC%2BC3cXotVKnsLY%3D 10.1007/s00401-010-0690-1 20419305 3568930
D. Puzzo L. Privitera M. Fa' A. Staniszewski G. Hashimoto F. Aziz et al. Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory Ann Neurol 2011 69 819 830 1:CAS:528:DC%2BC3MXltVyhtL0%3D 10.1002/ana.22313 21472769 4071456
A.M. Racine R.L. Koscik C.R. Nicholas L.R. Clark O.C. Okonkwo J.M. Oh et al. Cerebrospinal fluid ratios with Aβ42 predict preclinical brain β-amyloid accumulation Alzheimers Dement (Amst) 2016 2 27 38 10.1016/j.dadm.2015.11.006 26955655
A. Recchia P. Debetto A. Negro D. Guidolin S.D. Skaper P. Giusti α-synuclein and Parkinson’s disease FASEB J 2004 18 617 626 1:CAS:528:DC%2BD2cXjtFWitL8%3D 10.1096/fj.03-0338rev 15054084
T. Revesz J.L. Holton T. Lashley G. Plant B. Frangione A. Rostagno et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies Acta Neuropathol 2009 118 115 130 1:CAS:528:DC%2BD1MXmt1ahu7Y%3D 10.1007/s00401-009-0501-8 19225789 2844092
N. Rezaei-Ghaleh M. Amininasab K. Giller S. Kumar A. Stündl A. Schneider et al. Turn plasticity distinguishes different modes of amyloid-β aggregation J Am Chem Soc 2014 136 4913 4919 1:CAS:528:DC%2BC2cXktVSju7c%3D 10.1021/ja411707y 24617810
U.A. Rijal I. Kosterin S. Kumar A.C.A. Von H. Yamaguchi M. Fändrich et al. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer’s disease Brain 2014 137 887 903 10.1093/brain/awt362
A.E. Roher J.D. Lowenson S. Clarke C. Wolkow R. Wang R.J. Cotter et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer’s disease J Biol Chem 1993 268 3072 3083 1:CAS:528:DyaK3sXhsVGjsb0%3D 10.1016/S0021-9258(18)53661-9 8428986
G.C. Román T.K. Tatemichi T. Erkinjuntti J.L. Cummings J.C. Masdeu J.H. Garcia et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international WORKSHOP Neurology 1993 43 250 260 10.1212/wnl.43.2.250 8094895
R.F. Rosen Y. Tomidokoro A.S. Farberg J. Dooyema B. Ciliax T.M. Preuss et al. Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer’s disease Neurobiol Aging 2016 44 185 196 1:CAS:528:DC%2BC28XotFOrtrs%3D 10.1016/j.neurobiolaging.2016.04.019 27318146 4913040
A. Rostagno E. Cabrera T. Lashley J. Ghiso N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology Transl Neurodegener 2022 11 30 1:CAS:528:DC%2BB38XhvVShsrzL 10.1186/s40035-022-00303-3 35641972 9158284
C. Russo E. Violani S. Salis V. Venezia V. Dolcini G. Damonte et al. Pyroglutamate-modified amyloid beta-peptides - AbetaN3(pE) - strongly affect cultured neuron and astrocyte survival J Neurochem 2002 82 1480 1489 1:CAS:528:DC%2BD38XnsV2hs7g%3D 10.1046/j.1471-4159.2002.01107.x 12354296
T.C. Saido Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid Neurobiol Aging 1998 19 S69 S75 1:CAS:528:DyaK1cXisFyhtbo%3D 10.1016/s0197-4580(98)00033-5 9562472
T.C. Saido T. Iwatsubo D.M. Mann H. Shimada Y. Ihara S. Kawashima Dominant and differential deposition of distinct beta-amyloid peptide species, Abeta N3(pE), in senile plaques Neuron 1995 14 457 466 1:CAS:528:DyaK2MXjvFejsLk%3D 10.1016/0896-6273(95)90301-1 7857653
H.A. Scheidt J. Adler U. Zeitschel C. Höfling A. Korn M. Krueger et al. Pyroglutamate-modified amyloid β (11–40) fibrils are more toxic than wildtype fibrils but structurally very similar Chemistry 2017 23 15834 15838 1:CAS:528:DC%2BC2sXhs1CitLvM 10.1002/chem.201703909 28857302
H.A. Scheidt A. Das A. Korn M. Krueger S. Maiti D. Huster Structural characteristics of oligomers formed by pyroglutamate-modified amyloid β peptides studied by solid-state NMR Phys Chem Chem Phys 2020 22 16887 16895 1:CAS:528:DC%2BB3cXhtlCqurnO 10.1039/d0cp02307h 32666970
P. Scheltens M. Hallikainen T. Grimmer T. Duning A.A. Gouw C.E. Teunissen et al. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study Alzheimers Res Ther 2018 10 107 1:CAS:528:DC%2BC1MXmtFSitrY%3D 10.1186/s13195-018-0431-6 30309389 6182869
S. Schilling T. Lauber M. Schaupp S. Manhart E. Scheel G. Böhm et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro) Biochemistry 2006 45 12393 12399 1:CAS:528:DC%2BD28XpslWns70%3D 10.1021/bi0612667 17029395
G. Schilling A. Klevytska A.T.N. Tebbenkamp K. Juenemann J. Cooper V. Gonzales et al. Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models J Neuropathol Exp Neurol 2007 66 313 320 1:CAS:528:DC%2BD2sXltFWgsrc%3D 10.1097/nen.0b013e318040b2c8 17413322
S. Schilling U. Zeitschel T. Hoffmann U. Heiser M. Francke A. Kehlen et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer’s disease–like pathology Nat Med 2008 14 1106 1111 1:CAS:528:DC%2BD1cXht1Slu7zL 10.1038/nm.1872 18836460
D. Schlenzig S. Manhart Y. Cinar M. Kleinschmidt G. Hause D. Willbold et al. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides Biochemistry 2009 48 7072 7078 1:CAS:528:DC%2BD1MXnvFWkurk%3D 10.1021/bi900818a 19518051
P. Schober C. Boer L.A. Schwarte Correlation coefficients: appropriate use and interpretation Anesth Analg 2018 126 1763 1768 10.1213/ANE.0000000000002864 29481436
J. Schumacher J.L. Gunter S.A. Przybelski D.T. Jones J. Graff-Radford R. Savica et al. Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks Brain 2021 144 3212 3225 10.1093/brain/awab218 34114602 8634124
Y. Shin H.S. Cho H. Fukumoto T. Shimizu T. Shirasawa S.M. Greenberg et al. Aβ species, including IsoAsp23 Abeta, in Iowa-type familial cerebral amyloid angiopathy Acta Neuropathol 2003 105 252 258 1:CAS:528:DC%2BD3sXntV2hsA%3D%3D 10.1007/s00401-002-0639-0 12557012
J.R. Sims J.A. Zimmer C.D. Evans M. Lu P. Ardayfio J. Sparks et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial JAMA 2023 330 512 527 1:CAS:528:DC%2BB3sXhs1KhurvM 10.1001/jama.2023.13239 37459141 10352931
L.O. Soto-Rojas B.B. Campa-Córdoba C.R. Harrington A. Salas-Casas M. Hernandes-Alejandro I. Villanueva-Fierro et al. Insoluble vascular amyloid deposits trigger disruption of the neurovascular unit in Alzheimer’s disease brains Int J Mol Sci 2021 22 3654 1:CAS:528:DC%2BB3MXht1GktLnO 10.3390/ijms22073654 33915754 8036769
M.G. Spillantini M.L. Schmidt V.M. Lee J.Q. Trojanowski R. Jakes M. Goedert α-synuclein in Lewy bodies Nature 1997 388 839 840 1:CAS:528:DyaK2sXlslWru7o%3D 10.1038/42166 9278044
C.P. Sullivan E.A. Berg R. Elliott-Bryant J.B. Fishman A.C. McKee P.J. Morin et al. Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer’s disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core Neurosci Lett 2011 505 109 112 1:CAS:528:DC%2BC3MXhsVOjtbrJ 10.1016/j.neulet.2011.09.071 22001577 3253715
W.J. Thal T.C. Saido M. Fändrich Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease Acta Neuropathol 2015 129 167 182 1:CAS:528:DC%2BC2cXitFOgu77O 10.1007/s00401-014-1375-y 25534025
D.R. Thal U. Rüb M. Orantes H. Braak Phases of Aβ-deposition in the human brain and its relevance for the development of AD Neurology 2002 58 1791 1800 10.1212/wnl.58.12.1791 12084879
Y. Tomidokoro T. Lashley A. Rostagno T.A. Neubert M. Bojsen-Møller H. Braendgaard et al. Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan and Aβ) in the absence of compact plaques J Biol Chem 2005 280 36883 36894 1:CAS:528:DC%2BD2MXhtFKhtLzI 10.1074/jbc.M504038200 16091362
Y. Tomidokoro A. Rostagno T.A. Neubert Y. Lu G.W. Rebeck B. Frangione et al. Iowa variant of familial Alzheimer's disease: accumulation of posttranslationally modified AβD23N in parenchymal and cerebrovascular amyloid deposits Am J Pathol 2010 176 1841 1854 1:CAS:528:DC%2BC3cXltlelsrg%3D 10.2353/ajpath.2010.090636 20228223 2843474
P.H. Tu J.E. Galvin M. Baba B. Giasson T. Tomita S. Leight et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein Ann Neurol 1998 44 415 422 1:CAS:528:DyaK1cXmtFKls7w%3D 10.1002/ana.410440324 9749615
B.L. van der Gaag N.A.C. Deshayes J.J.P. Breve J.G.J.M. Bol A.J. Jonker J.J.M. Hoozemans et al. Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson's disease with dementia Acta Neuropathol 2024 147 14 1:CAS:528:DC%2BB2cXht1Wjsrg%3D 10.1007/s00401-023-02657-y 38198008 10781859
J. van Wetering H. Geut J.J. Bol Y. Galis E. Timmermans J.W.R. Twisk et al. Neuroinflammation is associated with Alzheimer's disease co-pathology in dementia with Lewy bodies Acta Neuropathol Commun 2024 12 73 1:CAS:528:DC%2BB2cXhtVGktbnJ 10.1186/s40478-024-01786-z 38715119 11075309
E.G.B. Vijverberg T.M. Axelsen A.R. Bihlet K. Henriksen F. Weber K. Fuchs et al. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD Alzheimers Res Ther 2021 13 142 1:CAS:528:DC%2BB3MXitVylsbvM 10.1186/s13195-021-00882-9 34425883 8381483
S. Walter T. Jumpertz M. Hüttenrauch I. Ogorek H. Gerber S.E. Storck et al. The metalloprotease ADAMTS4 generates N-truncated Aβ4-x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease Acta Neuropathol 2019 137 239 257 1:CAS:528:DC%2BC1cXitFyhtrjF 10.1007/s00401-018-1929-5 30426203
S. Weggen D. Beher Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer’s disease Alzheimers Res Ther 2012 4 9 1:CAS:528:DC%2BC38Xmtlyqtbw%3D 10.1186/alzrt107 22494386 3334542
O. Wirths T. Bethge A. Marcello A. Harmeier S. Jawhar P.J. Lucassen et al. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases J Neural Transm (Vienna) 2010 117 85 96 1:CAS:528:DC%2BD1MXhsFWmurbM 10.1007/s00702-009-0314-x 19823761
O. Wirths S. Walter I. Kraus H.W. Klafki M. Stazi T.J. Oberstein et al. N-truncated Aβ4-x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models Alzheimers Res Ther 2017 9 80 1:CAS:528:DC%2BC1cXnsVOnu7s%3D 10.1186/s13195-017-0309-z 28978359 5628465
Y. Yang D. Arseni W. Zhang M. Huang S. Lövestam M. Schweighauser et al. Cryo-EM structures of amyloid-β 42 filaments from human brains Science 2022 375 167 172 1:CAS:528:DC%2BB38XhvV2lt7s%3D 10.1126/science.abm7285 35025654 7612234
S. Zampar H.W. Klafki K. Sritharen T.A. Bayer J. Wiltfang A. Rostagno et al. N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer’s disease Neuropathol Appl Neurobiol 2020 46 673 685 1:CAS:528:DC%2BB3cXislWnt7rN 10.1111/nan.12637 32497293 8082844
S.X. Zhang-Nunes M.L.C. Maat-Schieman S.G. van Duinen R.A.C. Roos M.P. Frosch S.M. Greenberg The cerebral β-amyloid angiopathies: hereditary and sporadic Brain Pathol 2006 16 30 39 1:CAS:528:DC%2BD28XpsFeisbk%3D 10.1111/j.1750-3639.2006.tb00559.x 16612980 8095991